Form 4: Maze Therapeutics Grants RSUs to GC Courtney Phillips

Maze Therapeutics, Inc. granted 22,000 restricted stock units to its General Counsel and Corporate Secretary, Courtney Phillips, vesting over two years.

Summary

• Courtney Phillips, General Counsel and Corporate Secretary of Maze Therapeutics, Inc., was granted 22,000 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Maze Therapeutics' Common Stock upon settlement.
• The RSUs will vest in two equal tranches: 1/2 of the total award on September 1, 2026, and the remaining 1/2 on September 1, 2027.
• Vesting is contingent upon Courtney Phillips' continued service to the Issuer on each respective vesting date.
• Following this transaction, Courtney Phillips beneficially owns 22,000 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the RSU grant aligns management's interests with shareholders and is a standard practice for executive retention, indicating stability in key personnel.

Positives

• The grant of Restricted Stock Units aligns the interests of the General Counsel and Corporate Secretary with long-term shareholder value.
• Equity compensation serves as a retention mechanism for key management personnel.

Future Outlook

The vesting schedule for the Restricted Stock Units extends through September 2027, indicating an expectation of continued service from the General Counsel and Corporate Secretary.

Industry Context

The grant of Restricted Stock Units is a common form of equity compensation for executives in the biotechnology sector, designed to attract, retain, and incentivize key personnel by linking their compensation to the company's long-term performance and shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) to a General Counsel is a standard practice for executive compensation within the biotechnology and pharmaceutical industries, aligning executive interests with long-term shareholder value.
• This compensation structure is comparable to those utilized by other publicly traded biotech companies, such as Amgen, Gilead Sciences, or Biogen, which frequently employ equity awards to attract and retain key talent.

Stakeholder Impact

• Shareholders: The RSU grant aligns the interests of a key executive with long-term shareholder value, potentially fostering better decision-making for company growth.
• Employees: This type of executive compensation can set a precedent or standard for other equity incentive programs within the company.

Next Steps

• The Restricted Stock Units will vest in two tranches on September 1, 2026, and September 1, 2027, subject to continued service.

Key Dates

Keywords

Maze Therapeutics, MAZE, Restricted Stock Units, RSU, Equity Compensation, Insider Transaction, Executive Compensation, Corporate Governance, Biotechnology